Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleOncology

The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer

Jiajun Liu, Rengyun Liu, Xiaopei Shen, Guangwu Zhu, Biao Li and Mingzhao Xing
Journal of Nuclear Medicine February 2020, 61 (2) 177-182; DOI: https://doi.org/10.2967/jnumed.119.227652
Jiajun Liu
1Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and
2Department of Nuclear Medicine, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rengyun Liu
1Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaopei Shen
1Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guangwu Zhu
1Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Biao Li
2Department of Nuclear Medicine, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingzhao Xing
1Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 2 177-182
DOI 
https://doi.org/10.2967/jnumed.119.227652
PubMed 
31375570

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication February 20, 2019
  • Accepted for publication June 18, 2019
  • Published online February 3, 2020.

Article Versions

  • previous version (August 2, 2019 - 15:21).
  • previous version (August 12, 2019 - 06:13).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Jiajun Liu*,1,2,
  2. Rengyun Liu*,1,
  3. Xiaopei Shen1,
  4. Guangwu Zhu1,
  5. Biao Li2 and
  6. Mingzhao Xing1
  1. 1Laboratory for Cellular and Molecular Thyroid Research, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland; and
  2. 2Department of Nuclear Medicine, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  1. For correspondence or reprints contact: Mingzhao Xing, Johns Hopkins University School of Medicine, 1830 E. Monument St., Suite 333, Baltimore, MD 21287. E-mail: mxing1{at}jhmi.edu
View Full Text

Statistics from Altmetric.com

Cited By...

  • 94 Citations
  • 92 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Current practice in patients with differentiated thyroid cancer
    Martin Schlumberger, Sophie Leboulleux
    Nature Reviews Endocrinology 2021 17 3
  • Bone Mineral Density: Clinical Relevance and Quantitative Assessment
    Katherine N. Haseltine, Tariq Chukir, Pinar J. Smith, Justin T. Jacob, John P. Bilezikian, Azeez Farooki
    Journal of Nuclear Medicine 2021 62 4
  • Genomic alterations in thyroid cancer: biological and clinical insights
    Iñigo Landa, Maria E. Cabanillas
    Nature Reviews Endocrinology 2024 20 2
  • The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy
    Amandeep Singh, Jeehoon Ham, Joseph William Po, Navin Niles, Tara Roberts, Cheok Soon Lee
    Cells 2021 10 5
  • The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: A systematic review and meta‐analysis
    Bojie Chen, Yuan Shi, Yanan Xu, Jing Zhang
    Clinical Endocrinology 2021 94 5
  • <i>BRAF</i> and <i>TERT</i> promoter mutations: clinical application in thyroid cancer
    Jae Hoon Chung
    Endocrine Journal 2020 67 6
  • Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis
    Yi Luo, Hongyi Jiang, Weibo Xu, Xiao Wang, Ben Ma, Tian Liao, Yu Wang
    Frontiers in Oncology 2020 10
  • Pathogenesis of cancers derived from thyroid follicular cells
    James A. Fagin, Gnana P. Krishnamoorthy, Iñigo Landa
    Nature Reviews Cancer 2023 23 9
  • Characterization of Subtypes of BRAF-Mutant Papillary Thyroid Cancer Defined by Their Thyroid Differentiation Score
    Laura Boucai, Venkatraman Seshan, Michelle Williams, Jeffrey A Knauf, Mahesh Saqcena, Ronald A Ghossein, James A Fagin
    The Journal of Clinical Endocrinology & Metabolism 2022 107 4
  • Molecular Pathology of Non-familial Follicular Epithelial–Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification
    Paula Soares, Antónia Afonso Póvoa, Miguel Melo, João Vinagre, Valdemar Máximo, Catarina Eloy, José Manuel Cameselle-Teijeiro, Manuel Sobrinho-Simões
    Endocrine Pathology 2021 32 1

Article usage

Article usage: August 2019 to April 2025

AbstractFullPdf
Aug 2019785067
Sep 2019164014
Oct 2019109019
Nov 20198207
Dec 20196709
Jan 20209308
Feb 2020129391193
Mar 20203594576
Apr 20201642748
May 20201023342
Jun 2020963153
Jul 2020663038
Aug 2020952941
Sep 2020985442
Oct 2020794647
Nov 2020793649
Dec 2020594751
Jan 2021997061
Feb 2021888054
Mar 2021358848
Apr 2021286323
May 2021269156
Jun 2021243533
Jul 20211517137
Aug 20213412230
Sep 20212011159
Oct 20211812344
Nov 20211410341
Dec 20212210429
Jan 20221711846
Feb 20222511625
Mar 20221816531
Apr 2022158128
May 2022197741
Jun 2022175835
Jul 202299826
Aug 2022196734
Sep 202288436
Oct 2022287722
Nov 2022246618
Dec 2022286927
Jan 2023216029
Feb 202365012
Mar 2023610123
Apr 2023127121
May 2023157017
Jun 2023137618
Jul 2023105424
Aug 202387118
Sep 2023115621
Oct 2023116020
Nov 2023146926
Dec 2023256412
Jan 2024197425
Feb 202475621
Mar 2024106646
Apr 2024176637
May 202467731
Jun 2024155112
Jul 2024263917
Aug 2024123724
Sep 202494720
Oct 2024135833
Nov 202425426
Dec 2024125235
Jan 202544921
Feb 20251510920
Mar 2025711221
Apr 2025157458
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (2)
Journal of Nuclear Medicine
Vol. 61, Issue 2
February 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
Jiajun Liu, Rengyun Liu, Xiaopei Shen, Guangwu Zhu, Biao Li, Mingzhao Xing
Journal of Nuclear Medicine Feb 2020, 61 (2) 177-182; DOI: 10.2967/jnumed.119.227652

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
Jiajun Liu, Rengyun Liu, Xiaopei Shen, Guangwu Zhu, Biao Li, Mingzhao Xing
Journal of Nuclear Medicine Feb 2020, 61 (2) 177-182; DOI: 10.2967/jnumed.119.227652
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • KEY POINTS
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Genetic drivers of etiologic heterogeneity in thyroid cancer
  • Molecular and Proteomic Profiles of Radioiodine Refractory Papillary Thyroid Cancer
  • Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma
  • Bone Mineral Density: Clinical Relevance and Quantitative Assessment
  • Google Scholar

More in this TOC Section

Oncology

  • Chimeric antigen receptor (CAR) T cells Imaging: Clinical Needs and Strategies for Success
  • Metastatic NUT Midline Carcinoma
  • Radionuclides used in Nuclear Therapeutic Medicine: a brief history, properties and main relevant studies of radionuclides with mass number less than 100
Show more Oncology

Clinical

  • TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
  • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
Show more Clinical

Similar Articles

Keywords

  • BRAF V600E
  • TERT promoter mutation
  • radioiodine therapy
  • thyroid cancer
  • recurrence
SNMMI

© 2025 SNMMI

Powered by HighWire